The positive inotropic effect of endothelin-1 is mediated by mitochondrial reactive oxygen species

Life Sci. 2008 Aug 15;83(7-8):264-71. doi: 10.1016/j.lfs.2008.06.008. Epub 2008 Jun 24.

Abstract

We have previously demonstrated the participation of reactive oxygen species (ROS) in the positive inotropic effect of a physiological concentration of Angiotensin II (Ang II, 1 nM). The objective of the present work was to evaluate the role and source of ROS generation in the positive inotropic effect produced by an equipotent concentration of endothelin-1 (ET-1, 0.4 nM). Isolated cat ventricular myocytes were used to measure sarcomere shortening with a video-camera, superoxide anion (()O(2)(-)) with chemiluminescence, and ROS production and intracellular pH (pH(i)) with epifluorescence. The ET-1-induced positive inotropic effect (40.4+/-3.1%, n=10, p<0.05) was associated to an increase in ROS production (105+/-29 fluorescence units above control, n=6, p<0.05). ET-1 also induced an increase in ()O(2)(-) production that was inhibited by the NADPH oxidase blocker, apocynin, and by the blockers of mitochondrial ATP-sensitive K(+) channels (mK(ATP)), glibenclamide and 5 hydroxydecanoic acid. The ET-1-induced positive inotropic effect was inhibited by apocynin (0.3 mM; 6.3+/-6.6%, n=13), glibenclamide (50 microM; 8.8+/-3.5%, n=6), 5 hydroxydecanoic acid (500 microM; 14.1+/-8.1, n=9), and by scavenging ROS with MPG (2 mM; 0.92+/-5.6%, n=8). ET-1 enhanced proton efflux (J(H)) carried by the Na(+)/H(+) exchanger (NHE) after an acid load, effect that was blocked by MPG. Consistently, the ET-induced positive inotropic effect was also inhibited by the NHE selective blocker HOE642 (5 microM; 9.37+/-6.07%, n=7). The data show that the effect of a concentration of ET-1 that induces an increase in contractility of about 40% is totally mediated by an intracellular pathway triggered by mitochondrial ROS formation and stimulation of the NHE.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / antagonists & inhibitors
  • Angiotensin II / pharmacology
  • Animals
  • Cardiotonic Agents / antagonists & inhibitors
  • Cardiotonic Agents / pharmacology*
  • Cats
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Endothelin-1 / antagonists & inhibitors
  • Endothelin-1 / pharmacology*
  • Enzyme Inhibitors / pharmacology
  • Free Radical Scavengers / pharmacology
  • Glycine / analogs & derivatives
  • Glycine / pharmacology
  • Heart Ventricles / cytology
  • Heart Ventricles / metabolism
  • Mitochondria, Heart / metabolism*
  • Myocardial Contraction / drug effects
  • Myocytes, Cardiac / cytology
  • Myocytes, Cardiac / metabolism*
  • NADPH Oxidases / antagonists & inhibitors
  • NADPH Oxidases / metabolism
  • Potassium Channel Blockers / pharmacology
  • Potassium Channels / metabolism
  • Sarcomeres / metabolism
  • Sodium-Hydrogen Exchangers / antagonists & inhibitors
  • Sodium-Hydrogen Exchangers / metabolism
  • Sulfhydryl Compounds / pharmacology
  • Superoxides / antagonists & inhibitors
  • Superoxides / metabolism*
  • Vasoconstrictor Agents / antagonists & inhibitors
  • Vasoconstrictor Agents / pharmacology

Substances

  • Cardiotonic Agents
  • Endothelin-1
  • Enzyme Inhibitors
  • Free Radical Scavengers
  • N-(2-mercaptoproprionyl)-glycine
  • Potassium Channel Blockers
  • Potassium Channels
  • Sodium-Hydrogen Exchangers
  • Sulfhydryl Compounds
  • Vasoconstrictor Agents
  • Superoxides
  • Angiotensin II
  • NADPH Oxidases
  • Glycine